Startseite Kongressberichte 2019 15th International Conference on Malignant Lymphoma (ICML) INDOLENT NON-FOLLICULAR LYMPHOMA

INDOLENT NON-FOLLICULAR LYMPHOMA

A. Conconi, Ponderano (Italy), et al.

EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT

Authors Conclusion from the abstract: In patients with EMZL who received front‐line systemic treatment, POD24 is associated with poorer survival and may represent a useful endpoint in future prospective clinical trials.

 

A.J. Ferreri, Milan (Italy), et al.

INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL

Authors Conclusion from the abstract:  Intralesional rituximab is a safe and active treatment in pts with conjunctival indolent lymphoma. The addition of autologous serum is associated with improved response in some cases. Retreatment of local relapses can result in a second long‐lasting response.

 

A. Bruscaggin, Bellinzona (Switzerland), et al.

MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY

Authors Conclusion from the abstract: Genetic analysis of a large cohort of SMZLs cases identified four molecular subtypes characterized by unique deregulated genetic pathways, clinical outcome and potentially a molecular phenotype. These results can provide the basis for proposing the classification of SMZL into provisional molecular subtypes, that may lead to a conceptual edifice for developing precision therapies for SMZL patients.

 

P.L. Zinzani, Bologna (Italy), et al.

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Authors Conclusion from the abstract: PI3K‐delta inhibition with single‐agent umbralisib is active and well tolerated in pts with R/R MZL, achieving durable responses with chemotherapy‐free therapy.

 

J. Castillo, Boston, MA (USA), et al.

IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY 

Authors Conclusion from the abstract: Ibrutinib monotherapy can induce durable responses with acceptable toxicity in patients with BNS. Despite symptomatic and radiological improvements in the majority of patients, half of the patients can have persistence of disease in the CSF, and this should not represent treatment failure.

 

S.P. Treon, Boston, MA (USA), et al. 

IBRUTINIB MONOTHERAPY PRODUCES LONG- TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM’S MACROGLOBULINEMIA: FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821) 

Authors Conclusion from the abstract: The findings confirm that ibrutinib is highly active, and produces long‐term responses in previously treated WM. Prolonged ibrutinib therapy is associated with deeper responses, including VGPR. Response activity, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status.